Abstract：Objective To investigate the clinical efficacy of Lienal Polypeptide Injection combined with mFOLFOX6 chemotherapy on advanced colon cancer chemotherapy and observe its effect on the immune function. Methods From January 2013 to December 2016, in Department of Oncology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, 80 advanced colon cancer patients were selected, according to random number table method, they were divided into observation group and control group, with 40 cases in each group. Patients of two groups were given mFOLFOX6 regimen for 4 cycles, and the observation group was given Lienal Polypeptide Injection combined with chemotherapy. After chemotherapy, the peripheral blood T lymphocyte subsets, the recent curative effect, the side effects of chemotherapy and KPS score in the two groups were compared. Results After chemotherapy, the number of CD3+,CD4+ T lymphocytes and the ratio of CD4+/CD8+ in the observation group increased, the differences were statistically significant (P < 0.05), the number of CD8+ T lymphocytes decreased, the difference was statistically significant (P < 0.05); after chemotherapy, the number of CD3+, CD4+ T lymphocytes and the ratio of CD4+/CD8+ in control group decreased, the differences were statistically significant (P < 0.05), the number of CD8+ T lymphocytes increased, the difference was statistically significant (P < 0.05); after chemotherapy, the number of CD3+, CD4+ T cells and the ratio of CD4+/CD8+ T cells in the observation group were higher than those in the control group, the differences were statistically significant (P < 0.05), the number of CD8+ T cells was lower, the difference was statistically significant (P < 0.05). The recent curative effect, total effective rate and disease control rate in the observation group were slightly higher than those in the control group, but the differences were not statistically significant (P > 0.05). The incidence rates of Ⅲ+Ⅳ degree anemia, leukopeniawere in the observation group after chemotherapy were lower than those in the control group, the differences were statistically significant (P < 0.05), and the incidence rates of peripheral sensory neuropathy, nausea and vomiting, thrombocytopenia, diarrhea, liver function damage and renal function damage in the two groups were compared, the differences were not statistically significant (P > 0.05). Compared with the control group, the KPS score and quality of life improvement of the observation group were higher after chemotherapy, the differences were statistically significant (P < 0.05). Conclusion Lienal Polypeptide Injection can effectively correct the disturbance of immune function in patients with advanced colon cancer during chemotherapy, alleviate the blood toxicity caused by chemotherapy and improve the quality of life of patients.
毛山山 程小珍 崔荣花 元建华 王美清. 脾多肽注射液联合mFOLFOX6方案治疗晚期结肠癌的效果及对免疫功能的影响[J]. 中国医药导报, 2018, 15(20): 91-95.
MAO Shanshan CHENG Xiaozhen CUI Ronghua YUAN Jianghua WANG Meiqing. Effect of Lienal Polypeptide Injection combined with mFOLFOX6 chemotherapy in treatment of advanced colon cancer and influence on immune function. 中国医药导报, 2018, 15(20): 91-95.
[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] 王义艳，王建华，杨姗姗，等.2009-2013军队体检人群恶性肿瘤患病率与发病率分析[J].中华疾病控制杂志，2015，19（12）：1273-1277.
[3] Dotan E，Browner I，Hurria A，et al. Challenges in the management of older patients with colon cancer [J]. J Natl Compr Canc Netw，2012，10（2）：213-225.
[4] Xynos E，Gouvas N，Triantopoulou C，et al. Clinical practice guidelines for the surgical management of colon cancer： a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO [J]. Ann Gastroenterol，2016，29（1）：3-17.
[5] Stoehlmacher J. Prediction of efficacy and side effects of chemotherapy in colorectal cancer [J]. Recent Results Cancer Res. 2007，176 Suppl：s81-s88.
[6] 刘庆涛，余蓉，崔瑜霞，等.猪脾脏多肽的酶法制备及其生物活性研究[J].食品与药品，2010，12（5）：161-164.
[7] 田强，冯香芝，杨丽敏，等.鹅脾混合多肽对小鼠非特异性免疫功能的影响[J].医药导报，2015，34（2）：158-161.
[8] 周济昌.实用肿瘤内科学[M].2版.北京：人民卫生出版社，2010.
[9] Mima K，Sukawa Y，Nishihara R，et al. Fusobacterium nucleatum and T-cells in colorectal carcinoma [J]. JAMA Oncol，2015，1（5）：653-661.
[10] Denlinger CS，Engstrom PF. Colorectal cancer survivorship：movement matters [J]. Cancer Prev Res（Phlia），2011， 4（4）：502-511.
[11] Camus M，Tosolini M，Mlecnik B，et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence [J]. Cancer Res，2009，69（6）：2685-2693.
[12] 王俞，崔书中.恶性肿瘤患者的免疫功能状态及免疫治疗研究进展[J].中国肿瘤临床，2014，41（13）：876-879.
[13] Hirschey MD，DeBerardinis RJ，Diehl AME，et al. Dysregulated metabolism contributes to oncogenesis [J]. Semin Cancer Biol，2015，35（Suppl）：S129-S150.
[14] Mackall CL，Fleisher TA，Brown MR，et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy [J]. Blood，1997，89（10）：3700-3707.
[15] Fagnoni FF，Lozza L，Zibera C，et al. T-cell dynamics after high-dose chemotherapy in adults： elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence [J]. Immunology，2002，106（1）：27-37.
[16] 杨雪，焦艳梅，吴昊.CD4+ T淋巴细胞亚群研究进展[J].北京医学，2011，33（12）：1001-1003.
[17] Gras Navarro A，Bj?觟rklund AT，Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors [J]. Front Immunol，2015，6：202.
[18] De Aquino MTP，Malhotra A，Mishra MK，et al. Challenges and future perspectives of T cell immunotherapy in cancer [J]. Immunol Lett，2015，166（2）：117-133.
[19] 万福莺，孟岩.脾多肽对胆囊癌化疗患者细胞免疫功能的影响分析[J].中国实用医药，2017，12（9）：101-103.
[20] 武春涛，刘亮，徐永峰，等.脾多肽对胰腺癌根治术后化疗患者细胞免疫功能的影响[J].中国癌症杂志，2014， 24（12）：906-913.
[21] 赵玉山，温树伟，畅俊平，等.脾多肽注射液联合TACE治疗原发性肝癌及其对免疫功能的影响[J].世界华人消化杂志，2016，24（15）：2384-2389.
[22] 王丹丹，陈伟贤，夏文晋，等.脾多肽联合化疗治疗乳腺癌的临床疗效观察[J].中国现代医学杂志，2017，27（3）：93-96.
2018, Vol. 15 
京公网安备 11010502046598号